Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating restated by D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $10.00 price objective on the stock. D. Boral Capital’s target price suggests a potential upside of 255.87% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th.

Anixa Biosciences Price Performance

Shares of Anixa Biosciences stock opened at $2.81 on Wednesday. Anixa Biosciences has a 1 year low of $2.07 and a 1 year high of $5.03. The company has a market capitalization of $90.48 million, a P/E ratio of -7.21 and a beta of 0.90. The business has a 50-day moving average of $2.77 and a two-hundred day moving average of $3.04.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. On average, equities analysts anticipate that Anixa Biosciences will post -0.46 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Amit Kumar bought 43,000 shares of Anixa Biosciences stock in a transaction dated Wednesday, January 15th. The shares were bought at an average cost of $2.23 per share, with a total value of $95,890.00. Following the acquisition, the chief executive officer now owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The stock was bought at an average cost of $2.57 per share, with a total value of $25,700.00. Following the purchase, the director now owns 922,334 shares of the company’s stock, valued at $2,370,398.38. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 62,289 shares of company stock valued at $141,561. Insiders own 22.60% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds have recently bought and sold shares of the company. International Assets Investment Management LLC grew its position in Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after acquiring an additional 23,800 shares during the last quarter. Virtu Financial LLC bought a new position in Anixa Biosciences in the 3rd quarter valued at approximately $34,000. Westside Investment Management Inc. boosted its position in Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after buying an additional 21,100 shares in the last quarter. Finally, Tyler Stone Wealth Management grew its stake in shares of Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after buying an additional 21,008 shares during the last quarter. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.